retatrutide - Search News

Lilly, Retatrutide

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.

Continue reading

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug

3d

People Are Already Taking This Unapproved New Weight-Loss Drug

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

TipRanks on MSN

Eli Lilly’s retatrutide study: A new hope for CKD treatment?

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...

TRIUMPH-4 Results: Retatrutide Cuts Weight and Knee OA Pain

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

7hon MSN

Eli Lilly just delivered fantastic news to investors

Eli Lilly shares have climbed in the double digits this year.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results